Company: DMAC
Filing Date: 2025-08-01
Form Type: S-3
Source: 0001437749-25-024290
Chunk: 46

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-08-01
Form: S-3
Chunk 46
---
,000 |     |            |  0.87 | % |     |           |    30,000 |     |                        |    420,000 |     |            |  0.81 | % |
| John H. Perkins                                                        |     |                           |     50,070 |     |            |  0.10 | % |     |           |    28,570 |     |                        |     21,500 |     |            |  0.04 | % |
| Total                                                                  |     |                           | 27,705,320 |     |            |       |   |     |           | 8,606,425 |     |                        | 19,098,895 |     |            |       |   |

Material Relationships Between Selling Shareholders and DiaMedica

2025 Private Placement

On July 21, 2025, we entered into Securities Purchase Agreements with the selling shareholders pursuant to which we issued and sold to the selling shareholders an aggregate of 8,606,425 newly issued common shares, for aggregate gross proceeds of $30.1 million. The Private Placement closed on July 23, 2025, at which time we entered into registration rights agreements with the selling shareholders.

Pursuant to the terms of the Securities Purchase Agreements and the Registration Rights Agreement, we agreed to prepare and file with the SEC within 10 business days of the closing date a registration statement covering the resale of the common shares sold to the selling shareholders, and to use commercially reasonable best efforts to cause the registration statement to become effective within 30 days of the closing date in the event of no review by the SEC, or 75 days in the event of a review by the SEC. We agreed to use commercially reasonable best efforts to keep the registration statement effective until the date on which all of the common shares sold in the Private Placement are sold by the selling shareholders or are otherwise no longer “registrable securities” as defined in the registration rights agreement. We are registering the common shares to be sold by the selling shareholders under the registration statement of which this prospectus is a part to satisfy our obligation under the Securities Purchase Agreements. If we fail to meet the specified filing deadlines or keep the registration statement of which this prospectus is a part effective, subject to certain permitted exceptions, we will be required to pay liquidated damages to the selling shareholders. We also agreed, among other things, to indemnify the selling shareholders from certain liabilities and to pay